Company Filing History:
Years Active: 2008-2010
Title: Alisa Berlin: Innovator in Pharmaceutical Chemistry
Introduction
Alisa Berlin is a prominent inventor based in Jerusalem, Israel. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the synthesis of complex molecules. With a total of two patents to her name, her work has implications for both medical research and drug development.
Latest Patents
Alisa Berlin's latest patents include innovative methods for synthesizing sphingomyelin and its analogs. One of her notable inventions is titled "Sphingomyelin, intermediates thereof and methods for preparation of same." This patent describes novel cyclic and acyclic oxazaphospholanes, detailing their use in the synthesis of sphingomyelin and sphingomyelin analogs. Additionally, she has developed methods for producing synthetic sphingomyelins, including 2S, 3R stereoisomers of oxazaphospholanes and sphingomyelins. Another significant patent is the "Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril," which encompasses a detailed process for synthesizing this compound through a series of chemical reactions involving specific reactants and phase transfer catalysts.
Career Highlights
Throughout her career, Alisa Berlin has worked with notable companies in the pharmaceutical industry, including Bio-Lab, Inc. and Teva Pharmaceutical Industries Limited. Her experience in these organizations has allowed her to apply her innovative ideas in practical settings, contributing to advancements in drug formulation and synthesis.
Collaborations
Alisa has collaborated with esteemed colleagues such as Jean Hildesheim and Elimelech Rochlin. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical compounds.
Conclusion
Alisa Berlin's contributions to pharmaceutical chemistry through her patents and collaborations highlight her role as an influential inventor in the field. Her innovative approaches to synthesis continue to impact medical research and drug development.